ARMANDO ABERGEL

PROFESSEUR

Université Clermont Auvergne

France

Research Interests

Explore related searches

Professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Armando Abergel is a faculty member at Clermont Université in France. His research areas encompass chronic hepatitis, hepatocellular carcinoma, liver transplantation, and patient outcomes related to medical treatment costs. Recent publications include studies on the natural history of hepatitis delta, survival prediction in liver cancer patients, and the long-term effects of radiofrequency thermocoagulation for hemorrhoids.

Articles (14)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (5)

Marie Gladys Robert

Université Grenoble Alpes

FRANCE

View details

Thomas Haaf

Julius-Maximilians-Universität

GERMANY

View details

Daniel Ajzenberg

Sorbonne Université Faculté de Médecine

FRANCE

View details

Rodolphe Anty

FRANCE

View details

Ralf Weiskirchen

Medizinische Fakultät der RWTH Aachen

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

ARMANDO ABERGEL

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Editorial: Chronic Hepatitis Delta—We Need More Screening to Improve Knowledge on the Natural History

Editorial: Have you asked your patients about their difficulties in paying the medical costs of their treatment?

Editorial: How often can we get the right diagnosis after bone marrow transplant in patients with abnormal liver function tests?

AFP-DIAM Score to Predict Survival in Patients with Hepatocellular Carcinoma Before TACE: A French Multicenter Study

What can patients expect in the long term from radiofrequency thermocoagulation of hemorrhoids on bleeding, prolapse, quality of life, and recurrence: “no pain, no gain” or “no pain but a gain”?

Genetic Characterization of Rat Hepatic Stellate Cell Line PAV-1

Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?

Microsporidiosis after liver transplantation: A French nationwide retrospective study

Letter: is the AHHS score really useful in clinically severe alcoholic hepatitis?

Two Metabolomics Phenotypes of Human Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease According to Fibrosis Severity

Comparing Real World, Personalized, Multidisciplinary Tumor Board Recommendations with BCLC Algorithm: 321-Patient Analysis.

Extrahepatic portal vein obstruction (EHPVO) in cirrhosis

Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe fibrosis

Assessment of Malnutrition, Sarcopenia and Frailty in Patients with Cirrhosis: Which Tools Should We Use in Clinical Practice?

Collaborators (5)

Marie Gladys Robert

Thomas Haaf

Daniel Ajzenberg

Rodolphe Anty

Ralf Weiskirchen

Make your next move.